
Vir Biotechnology (VIR) Stock Forecast & Price Target
Vir Biotechnology (VIR) Analyst Ratings
Bulls say
Vir Biotechnology Inc. demonstrates a robust pipeline with promising clinical results, particularly in its hepatitis B and HDV programs, which could lead to significant upside potential for the company's stock as near-term readouts are anticipated. The company has effectively established a framework for value-based pricing, highlighting the therapeutic potential and competitive advantage of its combination regimen, especially in the context of critical interventions for compensated cirrhotic patients. Additionally, Vir's commitment to disciplined financial execution and a focused strategy enhances its clinical momentum as it enters 2025, suggesting a strong outlook in the realms of infectious diseases and oncology.
Bears say
Vir Biotechnology has reported a decline in expected revenue, with collaboration revenue projected to decrease from $86 million in 2023 to $102 million, primarily due to reduced partnerships. Additionally, the company's overall revenue estimate has dropped from $580 million in 2023 to $531 million, influenced by portfolio restructuring and prioritization efforts. Furthermore, a significant workforce reduction of 30% and the risk of unmet clinical trial outcomes for its drug candidates underscore ongoing challenges that contribute to a negative outlook on the company's stock prospects.
This aggregate rating is based on analysts' research of Vir Biotechnology and is not a guaranteed prediction by Public.com or investment advice.
Vir Biotechnology (VIR) Analyst Forecast & Price Prediction
Start investing in Vir Biotechnology (VIR)
Order type
Buy in
Order amount
Est. shares
0 shares